Rare bone infection study aims to uncover best treatment paths

NCT ID NCT07665866

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 100 adults diagnosed with skull base osteomyelitis, a rare and serious bone infection near the ear and skull base. Researchers will track how often the infection returns or leads to death within 12 months. The goal is to gather real-world data to help standardize care for this poorly understood condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors better understand how this rare infection progresses and lead to more standardized treatment guidelines.

What could go wrong

This is an observational study, not testing a new treatment. It may not directly improve patient outcomes, and results may take years to influence clinical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT EXTERNAL OTITIS (NECROTIZING/MALIGNANT OTITIS EXTERNA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease malignant otitis externa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lariboisière Hospital, 2 rue Ambroise Paré

    Paris, 75010, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••